Organon

Yahoo Finance • 12 days ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (... Full story

Yahoo Finance • 14 days ago

Insider trades: Boeing, Starbucks, Merck among notable names this week

[Close-up of male professional hands using mobile phone] Luis Alvarez This week, insider trading was seen across companies like Nike (NKE [https://seekingalpha.com/symbol/NKE]), Boeing (BA [https://seekingalpha.com/symbol/BA]) and Merck (... Full story

Yahoo Finance • 15 days ago

Interim Report - January-September 2025

Karolinska Development AB (publ) STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. “We are n... Full story

Yahoo Finance • 19 days ago

Organon cuts outlook despite Q3 beat amid JADA divestment

[Rolled newspaper with the headline Quarterly Results] Zerbor/iStock via Getty Images Organon (OGN [https://seekingalpha.com/symbol/OGN]) shares added ~3% in the premarket on Monday, even as the women’s health company lowered its full-yea... Full story

Yahoo Finance • 19 days ago

Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3

Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations , with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s full-year revenue guidance of $6.23 billi... Full story

Yahoo Finance • 30 days ago

Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN)

We recently published 11 Stocks Jim Cramer Discussed, Including A Potential “Worst Stock Ever”. Organon & Co. (NYSE:OGN) is one of the stocks Jim Cramer recently discussed. Organon & Co. (NYSE:OGN) is a women’s health company that provide... Full story

Yahoo Finance • last month

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings of its Audit Committee's investigati... Full story

Yahoo Finance • last month

Organon CEO stands down amid contraceptive sales malpractice probe

Organon CEO Kevin Ali has stepped down from his leading position at the company, following its board’s discovery of sales malpractice. This follows a probe from the board’s audit committee, which found that Organon was conducting “imprope... Full story

Yahoo Finance • last month

Organon slides to record low after leadership shakeup linked to wholesaler sales probe

_UPDATE: ADDS LATEST SHARE MOVEMENT_ Organon (NYSE:OGN [https://seekingalpha.com/symbol/OGN]) shares fell 22% on Monday after it appointed Joseph Morrissey, currently executive VP and head of manufacturing & supply, as interim CEO followi... Full story

Yahoo Finance • last month

Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities

Organon (OGN) said Monday its board has appointed the company's head of manufacturing and supply Jos PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

US Federal Government Selects Headwater Gold’s Spring Peak Project for FAST-41 Permitting Track

VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Headwater Gold Inc. (CSE: HWG) (OTCQB: HWAUF) (the "Company" or "Headwater") is pleased to announce that its exploration permit on the Spring Peak project, referred to as the... Full story

Yahoo Finance • 2 months ago

Pfizer – TrumpRx deal boosts Big Pharma to a record rally

[President Trump Delivers An Announcement From The Oval Office] Win McNamee/Getty Images News The world’s biggest pharma companies recorded their best weekly performance in years on Friday after Pfizer (NYSE:PFE [https://seekingalpha.com/... Full story

Yahoo Finance • 2 months ago

AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored... Full story

Yahoo Finance • 2 months ago

Ocugen gets EU approval for Prolia and Xgeva biosimilars

[Biosimilars pharmaceutical drug bottle on blue background. A safe biological drug that work like biologic medicine. 3d illustration.] Carl Lokko/iStock via Getty Images * Shanghai Henlius Biotech (2696.HK) and Organon (NYSE: NYSE:OGN [... Full story

Yahoo Finance • 3 months ago

Organon and Henlius get FDA nod for Amgen biosimilars

[Biosimilars pharmaceutical drug bottle on blue background. A safe biological drug that work like biologic medicine. 3d illustration.] Carl Lokko/iStock via Getty Images Shanghai Henlius Biotech and Organon (NYSE:OGN [https://seekingalpha... Full story

Yahoo Finance • 4 months ago

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif., August 12, 2025--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William... Full story

Yahoo Finance • 4 months ago

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings

We recently published 10 Big Names Bleed Double Digits. Organon & Co. (NYSE:OGN) is one of the worst-performing stocks on Tuesday. Organon fell for a second day on Tuesday, shedding 13.13 percent to close at $8.4 apiece following a disapp... Full story

Yahoo Finance • 4 months ago

Earnings call transcript: Organon Q2 2025 beats EPS expectations, stock volatile

Organon & Co reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an EPS of $1.00, compared to the forecasted $0.94, marking a 6.38% surprise. The company also reported a revenue of $1.59 billion, exceeding the... Full story

Yahoo Finance • 4 months ago

Organon Q2 2025 slides: Revenue guidance raised amid Women's Health strength

Organon & Co (NYSE:OGN) shares jumped over 6% in premarket trading after the company’s Q2 2025 earnings presentation revealed raised revenue guidance and continued progress on debt reduction, despite ongoing challenges from loss of exclusi... Full story

Yahoo Finance • 4 months ago

Organon shares surge over 8% as Q2 earnings top estimates, raises revenue outlook

JERSEY CITY, N.J. - On Tuesday, Organon (NYSE:OGN) reported second-quarter earnings that exceeded analyst expectations and raised its full-year revenue guidance, while making significant progress on debt reduction. The healthcare company’... Full story